Orexigen Options Suggest Contrave Diet Pill May Avoid Arena, Vivus Delays

Orexigen Therapeutics Inc. option traders are placing record bets the biotechnology company that’s losing money for a sixth straight year will succeed where two rivals have failed in introducing the first prescription diet pill in a decade.
Bloomberg